Novartis: Medical Researchers Using New Tools to Turn Science Fiction into Fact

Jay Bradner, president of the Novartis Institutes for BioMedical Research (NIBR) and Chief Medical Officer Vas Narasimhan, also head of Global Drug Development, share their outlook for innovation in 2017.

What's next in research and development at Novartis (No. 2 on the DiversityInc Top 50 Companies for Diversity list) ? At the company's annual earnings announcement on January 25, NIBR President Jay Bradner and Head of Global Drug Development Vas Narasimhan shared their outlook on where Novatis will focus its R&D efforts this year, what it means to be a translational drug hunting institute, and why the company insists on a collaborative approach to science. Here are a few highlights from the briefing:


An unprecedented opportunity

In his opening remarks, NIBR president Jay Bradner described how medical science is experiencing a unique moment in its development.

"The convergence of guiding insights into the hardwiring of disease, as well as the recent and radical expansion of the science of therapeutics, creates an unprecedented opportunity to render meaningful contributions to humanity," said Bradner.

Novartis aims to make the most of this opportunity by bolstering our investment in new tools that support high-quality science in the search for new medicines. For example, we're using the latest technological advances in DNA barcoding to expand our already massive chemical library, a key departure point for identifying potential new treatments. The goal is to go from 3 million molecules to 300 million in the next three years.

Novartis Survey Uncovers Real-World Impact of Immune Thrombocytopenia or ITP, a Rare Blood Disease, on Patients' Quality of Life

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%).

Originally Published by Novartis.

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).

Read More Show Less

Open Resources at Novartis Help Drive Innovation

With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

Originally Published by Novartis.

By K.E.D. Coan

"Back in Argentina, you never think of going for a real drug, but coming to Novartis completely changed what I thought was possible," says Bernardo Bazet Lyonnet, a postdoctoral researcher who first came to Novartis in 2016 as a Next Generation Scientist ( NGS). This program invites talented scientists from around the world for a bi-directional learning exchange at the Novartis campus in Basel, Switzerland.

Read More Show Less

Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

"In the advanced breast cancer setting, it is important to ensure we provide patients with treatment options that increase time to disease progression while also maintaining quality of life."

Originally Published by Novartis.

Novartis announced positive results from the third Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. MONALEESA-3 is the largest phase III trial to evaluate efficacy and safety of a CDK4/6 inhibitor plus fulvestrant in multiple advanced breast cancer patient populations - first-line and second-line settings[1]. These data will be presented as an oral presentation at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #1000) and published simultaneously in the Journal of Clinical Oncology.

Read More Show Less